| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | ML320 | CTRPv2 | pan-cancer | AAC | -0.032 | 0.4 |
| mRNA | BRD-K09587429 | CTRPv2 | pan-cancer | AAC | -0.036 | 0.4 |
| mRNA | GSK-1904529A | GDSC1000 | pan-cancer | AAC | 0.029 | 0.4 |
| mRNA | hyperforin | CTRPv2 | pan-cancer | AAC | -0.035 | 0.4 |
| mRNA | Bosutinib | GDSC1000 | pan-cancer | AAC | 0.029 | 0.4 |
| mRNA | ibrutinib | CTRPv2 | pan-cancer | AAC | 0.037 | 0.4 |
| mRNA | JQ-1 | CTRPv2 | pan-cancer | AAC | 0.028 | 0.4 |
| mRNA | C6-ceramide | CTRPv2 | pan-cancer | AAC | -0.033 | 0.4 |
| mRNA | ML258 | CTRPv2 | pan-cancer | AAC | -0.033 | 0.4 |
| mRNA | ISOX:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.031 | 0.4 |